MedTrace Logo

Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock

NCT04948372 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-07-01

No results posted yet for this study

Summary

This open-label, randomized controlled trial aimed to investigate the effect of a fixed dose of terlipressin added to usual care vs. usual care alone on renal perfusion in patients with septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Terlipressin treatment

Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.

DRUG

Usual care

Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.

Sponsors & Collaborators

  • Southeast University, China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-05-31
Completion
2020-06-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948372 on ClinicalTrials.gov